Advanced Search

 

Study ID Status Title Patient Level Data
240563/006 Completed A multicenter, double-blind, randomized, placebo controlled, parallel group study to evaluate the safety and efficacy of Intravenous SB 240563 (250mg and 750mg) in patients with asthma.
240563/017 Completed A double-blind, placebo controlled, parallel group study to assess tolerability and pharmacokinetics of three 250 mg subcutaneous doses of SB-240563 in male and female patients with asthma
240563/035 Completed A double blind, placebo controlled, dose rising study to assess safety and pharmacokinetics of SB-240563 in male patients with mild asthma
240563/036 Completed A Double Blind, Placebo Controlled, Parallel Group Study to Assess the Effect of 750 mg SB-240563 (Anti-IL-5) on Clinical Features, Cutaneous Late-Phase Reactions and Bronchial, Nasal, Skin, Bone Marrow and Blood Eosinophils in Male and Female Patients with Atopic Asthma
25000/541 Completed The Effect of Antimicrobial Therapy for Otitis Media on Pneumococcal Carriage and Antibiotic Resistance Study Listed on ClinicalStudyDataRequest.com
25000/547 Completed An Open, Non-Comparative Multicenter Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125 mg Twice Daily for 7 days for the Treatment of Bacterial Community-Acquired Pneumonia in adults. Study Listed on ClinicalStudyDataRequest.com
25000/555 Completed Evaluating the Impact of Amoxicillin/Clavulanate Potassium Therapy on Carriage of Susceptible and Resistant Streptococcus pneumoniae. Study Listed on ClinicalStudyDataRequest.com
25000/557 Completed A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Three Times Daily for 7 or 10 Days for the Treatment of Bacterial Community Acquired Pneumonia in Adults. Study Listed on ClinicalStudyDataRequest.com
25000/592 Completed An Open, Non-Comparative Multicenter Study to Assess the Efficacy and Safety of Oral AUGMENTIN SR 2000/125mg Twice Daily for 10 Days in the Treatment of Acute Bacterial Sinusitis in Adults. Study Listed on ClinicalStudyDataRequest.com
25000/593 Completed A randomized open label, 4 period, crossover study to determine the bioequivalence of scored tablets of pharmacokinetically enhanced AUGMENTIN (administered as two tablets which have been broken in half) to unscored whole tablets of pharmacokinetically enhanced AUGMENTIN in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
25000/600 Completed A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Twice Daily for 7 days in the Treatment of Adults with Bacterial Community Acquired Pneumonia. Study Listed on ClinicalStudyDataRequest.com
25000/601 Completed A Study to Determine the Bioequivalence of Reformulated Augmentin Suspension (improved stability) to Standard Marketed Suspension. Study Listed on ClinicalStudyDataRequest.com
25000/611 Completed A Randomized, Investigator-Blind, Multicenter Study to Assess the Efficacy of Oral AUGMENTIN ES-600 Twice Daily for 10 Days Versus Oral Zithromax Once Daily for 5 Days in the Treatment of Acute Otitis Media in Infants and Children. Study Listed on ClinicalStudyDataRequest.com
25000/620 Completed A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Three Times Daily for 7 or 10 Days in the Treatment of Adults with Community Acquired Pneumonia of Suspected Pneumococcal Origin. Study Listed on ClinicalStudyDataRequest.com
25000/627 Completed A randomized, double-blind, multicentre, parallel group study to assess the efficacy and safety of oral Augmentin SR 2000/125mg twice daily for 5 days versus a 7-day regimen in the treatment of acute exacerbation of chronic bronchitis Study Listed on ClinicalStudyDataRequest.com
25000/630 Completed A randomised, double-blind, double-dummy, multicentre, parallel group study to assess the efficacy and safety of oral Augmentin SR 2000/125mg twice daily for 5 days versus oral Augmentin 875/125mg twice daily for 7 days in the treatment of adults with acute exacerbations of chronic bronchitis. Study Listed on ClinicalStudyDataRequest.com
25000/643 Completed A bioequivalence study to compare the currently marketed formulation of augmentin with the ES 600 Strawberry Cream Suspension (4A) Study Listed on ClinicalStudyDataRequest.com
25000/665 Completed An open-label, randomized, period balanced, replicate, four-period crossover bioequivalence study comparing AUGMENTIN ES-600 strawberry cream formulation to the marketed suspension. Study Listed on ClinicalStudyDataRequest.com
257049/015 Completed Staggered study to evaluate safety and immunogenicity of GSK Biologicals RTS,S/AS02 candidate malaria vaccine, administered intramuscularly according to a 0,1,3-month schedule in semi-immune children aged 6 to 11 years in Gambia, a malaria endemic region Study Listed on ClinicalStudyDataRequest.com
257049/020 Completed Staggered study to evaluate safety & immunogenicity of GSK Biologicals RTS,S/AS02 candidate malaria vaccine, administered intramuscularly according to 0,1,3-month schedule in toddlers and children aged 1 through 5 years in Gambia, a malaria endemic region
257049/025 Completed A phase I, double-blind, randomized, controlled, study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ candidate vaccine, administered intramuscularly according to a 0, 1, 2-month vaccination schedule in children aged 1 through 4 Study Listed on ClinicalStudyDataRequest.com
257049/026 Completed A study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ candidate malaria vaccine RTS,S/AS02A, administered intramuscularly according to a 0, 1 and 2 month vaccination schedule in toddlers and children aged 1 to 4 years in a malaria-endemic region of Mozambique. Study Listed on ClinicalStudyDataRequest.com
257049/027 Completed Double-blind, randomized phase I/IIa human challenge study, to evaluate the safety, reactogenicity, immunogenicity, and preliminary efficacy after primary sporozoite challenge and rechallenge, of GSK Biologicals’ candidate malaria vaccines containing the antigen RTS,S adjuvanted with either AS02A or AS01B and administered intramuscularly at months 0, 1, 2 in healthy malaria-naive volunteers aged 18 - 45 years Study Listed on ClinicalStudyDataRequest.com
263855/004 Completed Randomised clinical study of the consistency of three lots of SB Biologicals dTpa vaccine in terms of immunogenicity and reactogenicity, and of the immunogenicity and reactogenicity of SB Biologicals pa vaccine and Lederle’s Td vaccine when administered as a booster dose to healthy adolescents (10-14 years old)
263855/017 Completed Open, five-year immunogenicity follow-up of subjects who previously received GSK Biologicals dTpa vaccine or GSKBiologicals pa vaccine and Lederles Td vaccine at 10 to 14 years of age in study 263855/004 (EXT: dTpa-004) Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.